Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.
The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.
Zacks Investment Research on MSN
Investors heavily search Pfizer Inc. (PFE): Here is what you need to know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...
Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The ...
Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...
Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...
Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...
Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...
Considerable on MSN
Pfizer channels COVID windfall into cancer
Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results